0KCC Stock Overview
OncoCyte Corporation, a precision diagnostics company, focuses on development and commercialization of proprietary tests in the United States and internationally.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
OncoCyte Corporation Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$2.49 |
| 52 Week High | US$5.60 |
| 52 Week Low | US$2.32 |
| Beta | 0.78 |
| 1 Month Change | -18.63% |
| 3 Month Change | n/a |
| 1 Year Change | -51.04% |
| 3 Year Change | -97.43% |
| 5 Year Change | n/a |
| Change since IPO | -96.93% |
Recent News & Updates
Recent updates
Shareholder Returns
| 0KCC | GB Biotechs | GB Market | |
|---|---|---|---|
| 7D | -5.1% | -0.4% | 2.2% |
| 1Y | -51.0% | -29.1% | 0.9% |
Price Volatility
| 0KCC volatility | |
|---|---|
| 0KCC Average Weekly Movement | n/a |
| Biotechs Industry Average Movement | 6.8% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in GB Market | 11.3% |
| 10% least volatile stocks in GB Market | 2.7% |
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2009 | 45 | Josh Riggs | www.oncocyte.com |
OncoCyte Corporation, a precision diagnostics company, focuses on development and commercialization of proprietary tests in the United States and internationally. The company is developing DetermaIO, a gene expression test that assesses the tumor microenvironment to predict response to immunotherapies; DetermaCNI, a blood-based monitoring tool for monitoring therapeutic efficacy in cancer patients; and VitaGraft, a blood-based solid organ transplantation monitoring test. It also provides testing services for biomarker discovery, assay design and development, clinical trial support, and various biomarker tests.
OncoCyte Corporation Fundamentals Summary
| 0KCC fundamental statistics | |
|---|---|
| Market cap | US$20.35m |
| Earnings (TTM) | -US$25.80m |
| Revenue (TTM) | US$1.50m |
13.5x
P/S Ratio-0.8x
P/E RatioIs 0KCC overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 0KCC income statement (TTM) | |
|---|---|
| Revenue | US$1.50m |
| Cost of Revenue | US$1.00m |
| Gross Profit | US$501.00k |
| Other Expenses | US$26.30m |
| Earnings | -US$25.80m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -3.12 |
| Gross Margin | 33.33% |
| Net Profit Margin | -1,716.37% |
| Debt/Equity Ratio | 0% |
How did 0KCC perform over the long term?
See historical performance and comparison